Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial

BACKGROUND: Cardiomyopathy is a leading cause of death in patients with Duchenne muscular dystrophy and myocardial damage precedes decline in left ventricular systolic function. We tested the efficacy of eplerenone on top of background therapy in patients with Duchenne muscular dystrophy with early...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Neurol
Main Authors: Raman, Subha V, Hor, Kan N, Mazur, Wojciech, Halnon, Nancy J, Kissel, John T, He, Xin, Tran, Tam, Smart, Suzanne, McCarthy, Beth, Taylor, Michael D, Jefferies, John L, Rafael-Fortney, Jill A, Lowe, Jeovanna, Roble, Sharon L, Cripe, Linda H
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361281/
https://ncbi.nlm.nih.gov/pubmed/25554404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(14)70318-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki